期刊文献+

Watchman左心耳封堵器的临床应用 被引量:13

Clinical application of Watchman occluder for left atrial appendage occlusion
下载PDF
导出
摘要 目的通过应用Watchman左心耳封堵器对非瓣膜病房颤患者左心耳进行封堵治疗,评价左心耳封堵效果与安全性。方法收集我院近期完成的应用Watchman左心耳封堵器进行左心耳封堵的临床资料,总结分析其基线资料,左心耳测量数据(心脏超声及造影)以及介入操作结果。结果 12例行左心耳封堵术治疗患者全部成功(成功率100%),其中男性6例、女性6例,年龄51~81(66.4±14.5)岁,房颤病史0.5~7(2.78±4.12)年。12例患者CHA2DS2-VASc评分为2~6(4.1±1.9)分。术中TEE测量左心耳开口最大直径为(19.7±2.2)mm;左心耳造影图像测得左心耳开口最大直径为(20.1±2.3)mm;两种方法测量的左心耳开口直径无显著差异(P〉0.05)。所用12枚Watchman封堵器直径(25.0±3.2)mm;植入左心耳内后TEE测量封堵器最大直径(20.3±5.8)mm,压缩率为(22.1±3.9)%。6例患者封堵后有少量残余分流,无手术相关并发症。结论应用Watchman左心耳封堵器进行左心耳封堵是安全、有效的,但需严格把握适应证,遵循严格的操作规范。 Objective To determine the efficiency and safety of Watchman occluder for left atrial appendage( LAA) occlusion in nonvalvular fibrillation atrial patients.Methods Clinical data of the patients undergoing LAA occlusion with Watchman occluder in our hospital from August to September 2014 were collected.Then the baseline information,measured data of LAA from ultrasound and visualization,and the results of interventional procedures were analyzed.Results Twelve patients were included in this study,including 6 males and 6 females,at an average year of 66.4 ± 14.5 years old( 51 to 81),and having AF for an average duration of 2.78 ± 4.12 years( 0.5 to 7),and all of them were successfully operated( 100%).The average CHA2DS2-VASc score was 4.1 ± 1.9( ranging from 2 to 6).The maximum LAA ostium was 19.7 ± 2.2 mm by transesophageal echocardiography( TEE),and 20.1 ± 2.3 mm by LAA angioplasty.There was no significant difference in the maximum ostium of LAA between the 2 measurement methods( P〉0.05).The average diameter of the 12 implanted Watchman occluders were 25.0 ± 3.2 mm.TEE indicated that the average maximum diameter of the implanted occluders was 20.3 ± 5.8 mm,with a maximum compression ratio of( 22.1 ± 3.9) %.There were 6 patients showing a small amount of residual shunt,but having no other operation-related complication.Conclusion Watchman occluder is safe and effective for LAA occlusion.But it is necessary to be performed under the indications and followed the practices strictly.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2014年第20期2129-2132,共4页 Journal of Third Military Medical University
关键词 心房颤动 左心耳封堵 Watchman封堵器 atrial fibrillation left atrial appendage occlusion Watchman occluder
  • 相关文献

参考文献1

共引文献607

同被引文献79

  • 1Camm A J, Kirchhof P, Lip G Y, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European So- ciety of Cardiology (ESC)EJ. Eur Heart J, 2010, 31 (19) ..2369-2429.
  • 2Reddy V Y, Doshi S K, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in pa- tients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage Sys tem for Embolic Protection in Patients with Atrial Fibril- lation) Trial[J]. Circulation, 2013,127 (6) : 720-729.
  • 3Landmesser U, Holmes D R Jr. Left atrial appendage clo- sure a percutaneous transcatheter approach {or stroke prevention in atrial fibrillation[J]. Eur Heart J, 2012,33 (6) :698 704.
  • 4Park J W, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation patients: initial European experience [J ]. Catheter Cardiovasc Interv, 2011,77 (5) : 700 -706.
  • 5Lam Y Y, Yip G W, Yu C M, et al. Left atrial appendage closure with Amplatzer cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience[J]. Catheter Cardiovasc Interv, 2012,79(5) : 794-800.
  • 6Bayard Y L,Omran H, Neuzil P, et al. PLAATO(Per- cutaneous Left Atrial Appendage Transcatheter Occlu- sion) for prevention of cardioembolic stroke in non-anti- coagulation eligible atrial fibrillation patients: result from the European PLAATO study[J]. Eurolnterven- tion, 2010,6(2) .. 220-226.
  • 7Holmes D R, Reddy V Y, Turi Z G, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial [ J ]. Lancet, 2009, 374 (9689) :534-542.
  • 8Bounhoure JP.Thrombotic risk factors and antithrombotic treatment in atrial fibrillation.Bull Acad Natl Med,2011,195(4-5):963-977.
  • 9Ganjehei L,Massumi A,Razavi M,et al.Stroke prevention in nonvalvular atrial fibrillation.Tex Heart Inst J,2011,38(4):350-352.
  • 10Wolberg AS,Aleman MM,Leiderman K,et al.Procoagulant activity in hemostasis and thrombosis:Virchow's triad revisited.Anesth Analg,2012,114(2):275-285.

引证文献13

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部